Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesPropanc Biopharma, Inc. Common Stock

Propanc Biopharma, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.79 USD 0.02 ( 1.13%)
Last update at 2026-11-09T15:44:00Z
VOLUME
5723
Market Cap
0.26M
P/E
0.04

Momentum Score

…

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.69
Low
1.81
High
52 Week Price Range
0.00
Low
0.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.77
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
0.50M
ROCE
57.35%
Diluted EPS TTM
0.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -2.79M -2.71M -2.14M -4.88M -5.87M
Net income -2.66M -2.66M -2.03M -4.74M -5.76M
Selling general administrative 1.53M 1.73M 1.58M 3.31M 2.35M
Reconciled depreciation 0.02M 0.01M 0.00M 0.00M 0.00M
Ebit -1.78M -1.99M -1.81M -3.49M -2.61M
Ebitda - -2.14M -1.69M -3.12M -4.56M
Operating income -1.78M -1.99M -1.81M -3.49M -2.61M
Interest expense 0.53M 0.57M 0.45M 1.75M 1.31M
Tax provision -0.13M -0.05M -0.11M -0.13M -0.12M
Interest income 0.00M 0.01M 0.00M 0.00M 0.00M
Net interest income -0.53M -0.56M -0.45M -1.75M -1.31M
Income tax expense -0.13M -0.05M -0.11M -0.13M -0.12M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.78M 1.99M 1.81M 3.49M 2.61M
Total other income expense net -0.48M -0.16M 0.12M 0.37M -1.94M
Net income from continuing ops -2.66M -2.66M -2.03M -4.74M -5.76M
Net income applicable to common shares -3.13M -3.36M -2.42M -4.74M -5.76M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 0.06M 0.08M 0.01M 0.10M 0.10M
Other current assets 0.01M 0.01M - - -
Total liab 3.18M 3.11M 3.08M 3.74M 4.40M
Total stockholder equity -3.12M -3.02M -3.07M -3.64M -4.30M
Other current liab 0.45M 0.18M 0.09M 0.21M 0.73M
Common stock 0.01M 0.00M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.24M 0.02M 0.26M 0.01M
Retained earnings -64.68M -61.56M -58.20M -55.78M -51.04M
Other assets 0.00M 0.00M 0.00M 0.00M 0.00M
Cash 0.01M 0.00M 0.00M 0.07M 0.00M
Total current liabilities 3.16M 3.06M 3.08M 3.74M 4.40M
Net debt 0.50M 1.03M 0.68M 1.54M 1.71M
Short term debt - - - - 1.71M
Short long term debt 0.51M 1.04M 0.68M 1.61M 1.71M
Other stockholder equity 1.29M 1.21M 1.09M 1.27M 1.07M
Property plant equipment 0.04M 0.06M 0.00M 0.03M 0.01M
Total current assets 0.02M 0.02M 0.01M 0.07M 0.09M
Net tangible assets -3.12M -3.03M -3.07M -3.65M -4.31M
Net receivables 0.00M 0.00M 0.00M 0.00M 0.01M
Accounts payable 0.97M 0.94M 1.00M 0.84M 0.92M
Non currrent assets other - - - - 0.01M
Non current assets total 0.04M 0.07M 0.01M 0.03M 0.01M
Capital lease obligations 0.04M 0.06M - 0.03M -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments - - - 0.00M -0.00M
Change to liabilities 0.08M 0.02M 0.18M -0.06M -0.16M
Total cashflows from investing activities - - - - -0.00M
Net borrowings 0.59M 0.77M 0.28M 1.47M 1.10M
Total cash from financing activities 1.11M 1.49M 1.06M 1.89M 2.12M
Change to operating activities 0.39M 0.15M 0.26M 0.27M 0.67M
Net income -2.66M -2.66M -2.03M -4.74M -5.76M
Change in cash 0.01M 0.00M -0.06M 0.06M -0.02M
Begin period cash flow 0.00M 0.00M 0.07M 0.00M 0.02M
End period cash flow 0.01M 0.00M 0.00M 0.07M 0.00M
Total cash from operating activities -1.11M -1.44M -1.15M -1.85M -2.06M
Issuance of capital stock 0.02M 0.10M 0.00M 0.45M 1.10M
Depreciation 0.02M 0.01M 0.00M 0.03M 0.00M
Other cashflows from financing activities - - - -0.03M -0.08M
Change to netincome 0.86M 1.00M 0.30M 1.92M 2.80M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.47M 0.17M 0.44M 0.21M 0.50M
Stock based compensation - - 0.08M 0.30M -
Other non cash items 0.33M 0.36M 0.28M 1.85M 0.62M
Free cash flow -1.11M -1.44M -1.15M -1.85M -2.06M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PPCB
Propanc Biopharma, Inc. Common Stock		 0.02
1.13%		 1.79 0.04 - - - -0.52
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Propanc Biopharma, Inc. Common Stock

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

302, 6 Butler Street, Camberwell, VIC, Australia, 3124

61 3 9882 0780

https://www.propanc.com

1

Name Title Year Born
Mr. James Nathanielsz Exec. Chairman, CEO, CFO, Treasurer & Sec. 1974
Dr. Julian Norman Kenyon ChB, M.D., MB Chief Scientific Officer, CTO & Director 1948
Prof. Klaus Kutz Chief Medical Officer & Member of Scientific Advisory Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…